In this review, we evaluate the main studies with "targeted therapy", alone or in combination with chemotherapy for the treatment of advanced gastric cancer. Although chemotherapy treatment of advanced gastric cancer obtained an interesting percentage of response, the duration of response is short with very few complete responses, time to progression is about 6-8 months, and overall survival under 11 months. Up to now, the inclusion of biological drugs to chemotherapy shows a modest increase in outcome, with the exception of trastuzumab. Interesting results with a significant advantage in terms of overall survival were reported with cisplatin plus fluoropyrimidine plus trastuzumab in patients with HER2-positive advanced gastric cancer in the ToGA trial. After these results, overall survival crossed the line of 11 months and arrived at 13 months. Currently, some clinical trials are ongoing to evaluate other biological agents, such as antiangiogenic and anti-epithelial growth factor receptor drugs, but results of large, clinical phase III trials are not still available. The results of ongoing and future research efforts will clarify the optimal use and survival benefit of targeted therapies for patients with advanced gastric cancer. © Permanyer Publications 2010.
New findings on the treatments of advanced gastric cancer: Targeted therapy (Part II) / Di Costanzo F., Giommoni E., Antonuzzo L.. - In: CANCER & CHEMOTHERAPY REVIEWS. - ISSN 1885-740X. - ELETTRONICO. - 5:(2010), pp. 33-43.
New findings on the treatments of advanced gastric cancer: Targeted therapy (Part II)
Giommoni E.;Antonuzzo L.
2010
Abstract
In this review, we evaluate the main studies with "targeted therapy", alone or in combination with chemotherapy for the treatment of advanced gastric cancer. Although chemotherapy treatment of advanced gastric cancer obtained an interesting percentage of response, the duration of response is short with very few complete responses, time to progression is about 6-8 months, and overall survival under 11 months. Up to now, the inclusion of biological drugs to chemotherapy shows a modest increase in outcome, with the exception of trastuzumab. Interesting results with a significant advantage in terms of overall survival were reported with cisplatin plus fluoropyrimidine plus trastuzumab in patients with HER2-positive advanced gastric cancer in the ToGA trial. After these results, overall survival crossed the line of 11 months and arrived at 13 months. Currently, some clinical trials are ongoing to evaluate other biological agents, such as antiangiogenic and anti-epithelial growth factor receptor drugs, but results of large, clinical phase III trials are not still available. The results of ongoing and future research efforts will clarify the optimal use and survival benefit of targeted therapies for patients with advanced gastric cancer. © Permanyer Publications 2010.I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



